Neurofeedback for managing food cravings in overweight individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project investigates whether individuals with overweight or obesity and high food cravings can learn to modify their brain responses to food cues through neurofeedback. The study has three main aims: to assess if neurofeedback from the craving network reduces craving network strength, to evaluate its impact on food cravings and eating behaviors, and to examine changes in resting state functional connectivity. Participants will receive either experimental or control feedback during the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ages 18 to 60 years
* Body mass index \>25 kg/m2
* \>2.37 Food Craving Inventory score

Exclusion Criteria:

* Current or past 6 months use of anti-obesity medications
* Weight-reduced state defined as \>10% weight reduction in the past 6 months.
* Nicotine use
* Current diagnosis of neurological or psychiatric disorder
* Obesity-related diseases such as type-2 diabetes
* Contraindications to MRI
* Baseline scanning with motion \>0.15mm frame to frame displacement.

Where it's running

• Yale MRRC Anlyan Center
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Kathleen A Garrison, PhD — Yale University
• Study coordinator: Kathleen A Garrison, PhD
• Email: kathleen.garrison@yale.edu
• Phone: 2037376232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GZC8072 tablets: safety and how the body handles it after a single dose in healthy people and after multiple doses in people who are overweight or obese

  This study tests GZC8072 tablets to see if they are safe and how they behave in the body after a single dose in healthy adults and after repeated doses in adults who are overweight or obese.

  Recruiting Phase 1 Gan & Lee Pharmaceuticals. · Beijing · NCT07784699

• Just-in-Time Practices to Prevent Weight Regain from Stopping Your Progress

  This trial tests whether sending brief mindfulness and self-compassion exercises right after weight regain or a missed weigh-in helps people stick with their long-term weight goals.

  Recruiting ORI Community and Evaluation Services · Springfield, Oregon · NCT07708064

• Olatorepatide in adults who are overweight or have obesity (without diabetes) test of safety and dosing

  This study tests olatorepatide versus placebo to see if it can safely help adults who are overweight or obese lose weight at different doses.

  Recruiting at 21 sites Phase 2 Regeneron Pharmaceuticals · Mobile, Alabama and 20 other locations · NCT07685808

• Metformin added to antidepressants for depression with obesity in Pakistani adults

  This study tests whether adding metformin to antidepressant therapy helps reduce depressive symptoms and BMI in adults with depression and overweight/obesity in Pakistan.

  Recruiting at 2 sites Riphah International University · Rawalpindi, Punjab Province and 1 other locations · NCT07654179

• Safety and drug levels of REGN20934 in adults with overweight or obesity

  This study tests REGN20934 to see if it is safe and how it behaves in the body in adults who are overweight or have obesity.

  Recruiting Phase 1 Regeneron Pharmaceuticals · Glendale, California · NCT07594093

• SYH2082 Injection: early-dose safety in adults with overweight or obesity

  This early-phase study tests whether a single dose and multiple doses of SYH2082 are safe and well tolerated in healthy adults who are overweight or have obesity.

  Recruiting Phase 1 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Nedlands, Western Australia · NCT07532655

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.